CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
Bexarotene +1 moredrug
Likely dose
Bexarotene 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00411632
NCT00411632Phase 2Completed
CompareCT.gov

A Phase II Study of Erlotinib (Tarceva) in Combination With Bexarotene (Targretin) in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center·interventional·Posted Dec 14, 2006·Updated Jan 29, 2020

In Brief

A Phase 2 clinical trial evaluating Bexarotene and Erlotinib for Lung Cancer. Completed, enrolled 37 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to evaluate the effectiveness of Tarceva® (OSI-774, erlotinib hydrochloride) in combination with Targretin® (bexarotene) in treating NSCLC. The safety of this treatment will also be studied, as well as the treatment's effect on different cells in the body and the participants' overall response.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsUnited States Department of Defense

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 14, 2006
Enrollment StartNov 29, 2006
Primary CompletionFeb 23, 2018
TodayJul 2, 2026
Enrollment to primary: 11.2 yearsPosted 19.6 years ago

Interventions

Bexarotenedrug

400 mg/m\^2 by mouth daily x 28 Days

Erlotinibdrug

150 mg by mouth daily x 28 Days